Improved renal allograft survival following donor-specific transfusions. III: Kinetics of mixed lymphocyte culture responses before and after transplantation
The essence of the clonal deletion model of the donor-specific transfusion (DST) effect is synergy between DST-priming and post-transplant immunosuppression. Using a sensitive kinetics assay of the mixed lymphocyte culture (MLC) response to donor and third-party stimulators, we compared the response...
Gespeichert in:
Veröffentlicht in: | Transplantation 1988, Vol.45 (1), p.127-132 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 132 |
---|---|
container_issue | 1 |
container_start_page | 127 |
container_title | Transplantation |
container_volume | 45 |
creator | BURLINGHAM, W. J GRAILER, A SONDEL, P. M SOLLINGER, H. W |
description | The essence of the clonal deletion model of the donor-specific transfusion (DST) effect is synergy between DST-priming and post-transplant immunosuppression. Using a sensitive kinetics assay of the mixed lymphocyte culture (MLC) response to donor and third-party stimulators, we compared the responses of controls (non-transfused healthy individuals) with those of patients who either had no rejection episodes in the first week posttransplant (group 1) or who had DST-type (greater than 3d onset) rejection episodes (group 2). We found that group 2 patients had normal or above-normal MLC responses after DST plus azathioprine (AZA) pretransplant treatment, but had a reduced/delayed posttransplant anti-donor MLC following reversal of early rejections (P = .05 compared with controls). Group 1 patients had a nonspecifically reduced MLC after DST + AZA treatment (P less than .02 compared with controls), while posttransplant MLC responses showed a return to normal (pretransfusion) levels. These data suggest a synergy of DST with immunosuppressive drug that induced MLC hyporesponsiveness, but only in patients who received anti-lymphoblast globulin or a sustained high dose immunosuppression in the early posttransplant period. |
doi_str_mv | 10.1097/00007890-198801000-00028 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_78098163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>14856739</sourcerecordid><originalsourceid>FETCH-LOGICAL-p181t-6645bf1a1da9f472196af54991a875b6c448aa5b4c77b4fffd45c1f304e6387b3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi1EVZaWn4DkA-KWYq8df3BDFR8RlbjQ82ri2MXIiYPtbNkfw39lpK64Ymlk-Z1n3vEMIZSzG86sfsfwaGNZx60xjOOrw9ibZ2THeyE7xQx7TnaMSd5xIfQL8rLWn4j0QutLcrm3ai-k3pE_w7yWfPQTLX6BRCGl_FAgNFq3coxHlEJG7TEuD3TKSy5dXb2LITraCiw1bDXmpd7QYRje069x8S26SnOgc_yNtuk0rz-yOzVP3ZbaVjx2qiuW-EpHHzIKsEwUW_ryZLkmWBo0tL0mFwFS9a_O9xW5__Tx--2X7u7b5-H2w123csNbp5Tsx8CBT2CD1HtuFYReWsvB6H5UTkoD0I_SaT3KEMIke8eDYNIrYfQorsjbJ1_cxa_N13aYY3U-4Ud83upBG2YNV-K_IJemV1pYBF-fwW2c_XRYS5yhnA7nxWP-zTkP1UEKOLeL9R-m0UQqLv4CScyXmw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14856739</pqid></control><display><type>article</type><title>Improved renal allograft survival following donor-specific transfusions. III: Kinetics of mixed lymphocyte culture responses before and after transplantation</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>BURLINGHAM, W. J ; GRAILER, A ; SONDEL, P. M ; SOLLINGER, H. W</creator><creatorcontrib>BURLINGHAM, W. J ; GRAILER, A ; SONDEL, P. M ; SOLLINGER, H. W</creatorcontrib><description>The essence of the clonal deletion model of the donor-specific transfusion (DST) effect is synergy between DST-priming and post-transplant immunosuppression. Using a sensitive kinetics assay of the mixed lymphocyte culture (MLC) response to donor and third-party stimulators, we compared the responses of controls (non-transfused healthy individuals) with those of patients who either had no rejection episodes in the first week posttransplant (group 1) or who had DST-type (greater than 3d onset) rejection episodes (group 2). We found that group 2 patients had normal or above-normal MLC responses after DST plus azathioprine (AZA) pretransplant treatment, but had a reduced/delayed posttransplant anti-donor MLC following reversal of early rejections (P = .05 compared with controls). Group 1 patients had a nonspecifically reduced MLC after DST + AZA treatment (P less than .02 compared with controls), while posttransplant MLC responses showed a return to normal (pretransfusion) levels. These data suggest a synergy of DST with immunosuppressive drug that induced MLC hyporesponsiveness, but only in patients who received anti-lymphoblast globulin or a sustained high dose immunosuppression in the early posttransplant period.</description><identifier>ISSN: 0041-1337</identifier><identifier>EISSN: 1534-6080</identifier><identifier>DOI: 10.1097/00007890-198801000-00028</identifier><identifier>PMID: 2962347</identifier><identifier>CODEN: TRPLAU</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Azathioprine - administration & dosage ; Biological and medical sciences ; Blood Transfusion ; Clone Cells - immunology ; Graft Enhancement, Immunologic ; Graft Rejection ; Humans ; Immunosuppression ; Kidney Transplantation ; Lymphocyte Activation ; Lymphocyte Culture Test, Mixed ; Lymphocyte Depletion ; Medical sciences ; Models, Biological ; Premedication ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; Tissue Donors</subject><ispartof>Transplantation, 1988, Vol.45 (1), p.127-132</ispartof><rights>1988 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7673461$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2962347$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BURLINGHAM, W. J</creatorcontrib><creatorcontrib>GRAILER, A</creatorcontrib><creatorcontrib>SONDEL, P. M</creatorcontrib><creatorcontrib>SOLLINGER, H. W</creatorcontrib><title>Improved renal allograft survival following donor-specific transfusions. III: Kinetics of mixed lymphocyte culture responses before and after transplantation</title><title>Transplantation</title><addtitle>Transplantation</addtitle><description>The essence of the clonal deletion model of the donor-specific transfusion (DST) effect is synergy between DST-priming and post-transplant immunosuppression. Using a sensitive kinetics assay of the mixed lymphocyte culture (MLC) response to donor and third-party stimulators, we compared the responses of controls (non-transfused healthy individuals) with those of patients who either had no rejection episodes in the first week posttransplant (group 1) or who had DST-type (greater than 3d onset) rejection episodes (group 2). We found that group 2 patients had normal or above-normal MLC responses after DST plus azathioprine (AZA) pretransplant treatment, but had a reduced/delayed posttransplant anti-donor MLC following reversal of early rejections (P = .05 compared with controls). Group 1 patients had a nonspecifically reduced MLC after DST + AZA treatment (P less than .02 compared with controls), while posttransplant MLC responses showed a return to normal (pretransfusion) levels. These data suggest a synergy of DST with immunosuppressive drug that induced MLC hyporesponsiveness, but only in patients who received anti-lymphoblast globulin or a sustained high dose immunosuppression in the early posttransplant period.</description><subject>Azathioprine - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Blood Transfusion</subject><subject>Clone Cells - immunology</subject><subject>Graft Enhancement, Immunologic</subject><subject>Graft Rejection</subject><subject>Humans</subject><subject>Immunosuppression</subject><subject>Kidney Transplantation</subject><subject>Lymphocyte Activation</subject><subject>Lymphocyte Culture Test, Mixed</subject><subject>Lymphocyte Depletion</subject><subject>Medical sciences</subject><subject>Models, Biological</subject><subject>Premedication</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><subject>Tissue Donors</subject><issn>0041-1337</issn><issn>1534-6080</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1988</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi1EVZaWn4DkA-KWYq8df3BDFR8RlbjQ82ri2MXIiYPtbNkfw39lpK64Ymlk-Z1n3vEMIZSzG86sfsfwaGNZx60xjOOrw9ibZ2THeyE7xQx7TnaMSd5xIfQL8rLWn4j0QutLcrm3ai-k3pE_w7yWfPQTLX6BRCGl_FAgNFq3coxHlEJG7TEuD3TKSy5dXb2LITraCiw1bDXmpd7QYRje069x8S26SnOgc_yNtuk0rz-yOzVP3ZbaVjx2qiuW-EpHHzIKsEwUW_ryZLkmWBo0tL0mFwFS9a_O9xW5__Tx--2X7u7b5-H2w123csNbp5Tsx8CBT2CD1HtuFYReWsvB6H5UTkoD0I_SaT3KEMIke8eDYNIrYfQorsjbJ1_cxa_N13aYY3U-4Ud83upBG2YNV-K_IJemV1pYBF-fwW2c_XRYS5yhnA7nxWP-zTkP1UEKOLeL9R-m0UQqLv4CScyXmw</recordid><startdate>1988</startdate><enddate>1988</enddate><creator>BURLINGHAM, W. J</creator><creator>GRAILER, A</creator><creator>SONDEL, P. M</creator><creator>SOLLINGER, H. W</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>1988</creationdate><title>Improved renal allograft survival following donor-specific transfusions. III: Kinetics of mixed lymphocyte culture responses before and after transplantation</title><author>BURLINGHAM, W. J ; GRAILER, A ; SONDEL, P. M ; SOLLINGER, H. W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p181t-6645bf1a1da9f472196af54991a875b6c448aa5b4c77b4fffd45c1f304e6387b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1988</creationdate><topic>Azathioprine - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Blood Transfusion</topic><topic>Clone Cells - immunology</topic><topic>Graft Enhancement, Immunologic</topic><topic>Graft Rejection</topic><topic>Humans</topic><topic>Immunosuppression</topic><topic>Kidney Transplantation</topic><topic>Lymphocyte Activation</topic><topic>Lymphocyte Culture Test, Mixed</topic><topic>Lymphocyte Depletion</topic><topic>Medical sciences</topic><topic>Models, Biological</topic><topic>Premedication</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><topic>Tissue Donors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BURLINGHAM, W. J</creatorcontrib><creatorcontrib>GRAILER, A</creatorcontrib><creatorcontrib>SONDEL, P. M</creatorcontrib><creatorcontrib>SOLLINGER, H. W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BURLINGHAM, W. J</au><au>GRAILER, A</au><au>SONDEL, P. M</au><au>SOLLINGER, H. W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Improved renal allograft survival following donor-specific transfusions. III: Kinetics of mixed lymphocyte culture responses before and after transplantation</atitle><jtitle>Transplantation</jtitle><addtitle>Transplantation</addtitle><date>1988</date><risdate>1988</risdate><volume>45</volume><issue>1</issue><spage>127</spage><epage>132</epage><pages>127-132</pages><issn>0041-1337</issn><eissn>1534-6080</eissn><coden>TRPLAU</coden><abstract>The essence of the clonal deletion model of the donor-specific transfusion (DST) effect is synergy between DST-priming and post-transplant immunosuppression. Using a sensitive kinetics assay of the mixed lymphocyte culture (MLC) response to donor and third-party stimulators, we compared the responses of controls (non-transfused healthy individuals) with those of patients who either had no rejection episodes in the first week posttransplant (group 1) or who had DST-type (greater than 3d onset) rejection episodes (group 2). We found that group 2 patients had normal or above-normal MLC responses after DST plus azathioprine (AZA) pretransplant treatment, but had a reduced/delayed posttransplant anti-donor MLC following reversal of early rejections (P = .05 compared with controls). Group 1 patients had a nonspecifically reduced MLC after DST + AZA treatment (P less than .02 compared with controls), while posttransplant MLC responses showed a return to normal (pretransfusion) levels. These data suggest a synergy of DST with immunosuppressive drug that induced MLC hyporesponsiveness, but only in patients who received anti-lymphoblast globulin or a sustained high dose immunosuppression in the early posttransplant period.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>2962347</pmid><doi>10.1097/00007890-198801000-00028</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-1337 |
ispartof | Transplantation, 1988, Vol.45 (1), p.127-132 |
issn | 0041-1337 1534-6080 |
language | eng |
recordid | cdi_proquest_miscellaneous_78098163 |
source | MEDLINE; Journals@Ovid Complete |
subjects | Azathioprine - administration & dosage Biological and medical sciences Blood Transfusion Clone Cells - immunology Graft Enhancement, Immunologic Graft Rejection Humans Immunosuppression Kidney Transplantation Lymphocyte Activation Lymphocyte Culture Test, Mixed Lymphocyte Depletion Medical sciences Models, Biological Premedication Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system Tissue Donors |
title | Improved renal allograft survival following donor-specific transfusions. III: Kinetics of mixed lymphocyte culture responses before and after transplantation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T14%3A19%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Improved%20renal%20allograft%20survival%20following%20donor-specific%20transfusions.%20III:%20Kinetics%20of%20mixed%20lymphocyte%20culture%20responses%20before%20and%20after%20transplantation&rft.jtitle=Transplantation&rft.au=BURLINGHAM,%20W.%20J&rft.date=1988&rft.volume=45&rft.issue=1&rft.spage=127&rft.epage=132&rft.pages=127-132&rft.issn=0041-1337&rft.eissn=1534-6080&rft.coden=TRPLAU&rft_id=info:doi/10.1097/00007890-198801000-00028&rft_dat=%3Cproquest_pubme%3E14856739%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=14856739&rft_id=info:pmid/2962347&rfr_iscdi=true |